25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALLO (Allogene) Stock Analysis
Buy, Hold or Sell?

Let's analyze Allogene together

I guess you are interested in Allogene Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Allogene’s Financial Insights
  • 📈 Technical Analysis (TA) – Allogene’s Price Targets

I'm going to help you getting a better view of Allogene Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Allogene Therapeutics Inc

I send you an email if I find something interesting about Allogene Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Allogene (30 sec.)










1.2. What can you expect buying and holding a share of Allogene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.76
Expected worth in 1 year
$1.41
How sure are you?
24.1%

+ What do you gain per year?

Total Gains per Share
$-0.35
Return On Investment
-28.9%

For what price can you sell your share?

Current Price per Share
$1.20
Expected price per share
$0.8621 - $1.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Allogene (5 min.)




Live pricePrice per Share (EOD)
$1.20
Intrinsic Value Per Share
$-3.80 - $-4.14
Total Value Per Share
$-2.03 - $-2.38

2.2. Growth of Allogene (5 min.)




Is Allogene growing?

Current yearPrevious yearGrowGrow %
How rich?$385.3m$544.9m-$98.3m-22.0%

How much money is Allogene making?

Current yearPrevious yearGrowGrow %
Making money-$63m-$72.5m$9.4m15.0%
Net Profit Margin68,112.5%-255,940.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Allogene (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#156 / 884

Most Revenue
#876 / 884

Most Profit
#820 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Allogene?

Welcome investor! Allogene's management wants to use your money to grow the business. In return you get a share of Allogene.

First you should know what it really means to hold a share of Allogene. And how you can make/lose money.

Speculation

The Price per Share of Allogene is $1.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allogene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allogene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.76. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allogene.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.27-22.8%-0.29-24.0%-0.33-27.6%-0.34-28.4%-0.33-27.2%-0.29-23.8%
Usd Book Value Change Per Share-0.17-14.0%-0.09-7.2%-0.15-12.5%-0.18-14.9%-0.05-4.2%0.065.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.17-14.0%-0.09-7.2%-0.15-12.5%-0.18-14.9%-0.05-4.2%0.065.1%
Usd Price Per Share1.46-2.18-3.96-4.83-13.74-14.84-
Price to Earnings Ratio-1.34--1.88--3.03--3.45--12.24--15.55-
Price-to-Total Gains Ratio-8.68--5.58--2.77--12.63--78.36--70.10-
Price to Book Ratio0.83-1.06-1.61-1.74-3.29-4.07-
Price-to-Total Gains Ratio-8.68--5.58--2.77--12.63--78.36--70.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.2
Number of shares833
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.05
Usd Total Gains Per Share-0.09-0.05
Gains per Quarter (833 shares)-72.33-42.11
Gains per Year (833 shares)-289.33-168.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-289-2990-168-178
20-579-5880-337-346
30-868-8770-505-514
40-1157-11660-674-682
50-1447-14550-842-850
60-1736-17440-1011-1018
70-2025-20330-1179-1186
80-2315-23220-1347-1354
90-2604-26110-1516-1522
100-2893-29000-1684-1690

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.029.00.00.0%0.029.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.022.00.024.1%7.022.00.024.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.022.00.024.1%7.022.00.024.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Allogene Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.168-0.087-48%-0.150-11%-0.179+6%-0.051-70%0.061-377%
Book Value Per Share--1.7622.042-14%2.491-29%2.578-32%3.420-48%3.012-41%
Current Ratio--9.7129.963-3%11.734-17%10.682-9%12.075-20%12.765-24%
Debt To Asset Ratio--0.2410.222+9%0.197+22%0.199+21%0.159+51%0.186+30%
Debt To Equity Ratio--0.3180.286+11%0.246+29%0.250+27%0.194+64%0.161+98%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--476801271.680677427097.440-30%1179618136.640-60%1356203211.147-65%3441134477.440-86%4067797407.951-88%
Eps---0.273-0.288+6%-0.332+21%-0.341+25%-0.326+19%-0.285+5%
Ev To Ebitda Ratio---2.110-2.822+34%-4.351+106%-4.638+120%-14.371+581%-19.287+814%
Free Cash Flow Per Share---0.242-0.226-7%-0.260+7%-0.247+2%-0.241-1%-0.212-13%
Free Cash Flow To Equity Per Share---0.178-0.079-56%-0.151-16%-0.161-10%-0.045-75%0.100-278%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.139----------
Intrinsic Value_10Y_min---3.796----------
Intrinsic Value_1Y_max---0.907----------
Intrinsic Value_1Y_min---0.891----------
Intrinsic Value_3Y_max---2.350----------
Intrinsic Value_3Y_min---2.251----------
Intrinsic Value_5Y_max---3.341----------
Intrinsic Value_5Y_min---3.133----------
Market Cap262477209.600-22%319347271.680476833597.440-33%865081136.640-63%1056653044.480-70%3005910877.440-89%3244874503.680-90%
Net Profit Margin---681.125-100%-2559.4050%-1162.7180%-996.7990%-687.4480%
Operating Margin---675.170-100%-2470.7150%-1121.9750%-972.2660%-670.5280%
Operating Ratio----687.3860%3203.407-100%1507.904-100%1319.079-100%909.710-100%
Pb Ratio0.681-22%0.8291.061-22%1.606-48%1.738-52%3.294-75%4.074-80%
Pe Ratio-1.099+18%-1.337-1.877+40%-3.030+127%-3.452+158%-12.240+816%-15.547+1063%
Price Per Share1.200-22%1.4602.180-33%3.955-63%4.831-70%13.743-89%14.835-90%
Price To Free Cash Flow Ratio-1.237+18%-1.506-2.525+68%-3.781+151%-5.095+238%-15.781+948%-18.469+1127%
Price To Total Gains Ratio-7.135+18%-8.681-5.584-36%-2.768-68%-12.630+45%-78.364+803%-70.101+707%
Quick Ratio--17.24216.809+3%20.859-17%18.796-8%20.850-17%21.397-19%
Return On Assets---0.118-0.110-6%-0.108-8%-0.108-8%-0.088-25%-0.094-20%
Return On Equity---0.155-0.142-8%-0.135-13%-0.135-13%-0.107-31%-0.105-32%
Total Gains Per Share---0.168-0.087-48%-0.150-11%-0.179+6%-0.051-70%0.061-377%
Usd Book Value--385393000.000446589500.000-14%544902000.000-29%563834000.000-32%748147200.000-48%658724482.759-41%
Usd Book Value Change Per Share---0.168-0.087-48%-0.150-11%-0.179+6%-0.051-70%0.061-377%
Usd Book Value Per Share--1.7622.042-14%2.491-29%2.578-32%3.420-48%3.012-41%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--476801271.680677427097.440-30%1179618136.640-60%1356203211.147-65%3441134477.440-86%4067797407.951-88%
Usd Eps---0.273-0.288+6%-0.332+21%-0.341+25%-0.326+19%-0.285+5%
Usd Free Cash Flow---53028000.000-49528750.000-7%-56870500.000+7%-54070166.667+2%-52661400.000-1%-46286827.586-13%
Usd Free Cash Flow Per Share---0.242-0.226-7%-0.260+7%-0.247+2%-0.241-1%-0.212-13%
Usd Free Cash Flow To Equity Per Share---0.178-0.079-56%-0.151-16%-0.161-10%-0.045-75%0.100-278%
Usd Market Cap262477209.600-22%319347271.680476833597.440-33%865081136.640-63%1056653044.480-70%3005910877.440-89%3244874503.680-90%
Usd Price Per Share1.200-22%1.4602.180-33%3.955-63%4.831-70%13.743-89%14.835-90%
Usd Profit---59733000.000-63080750.000+6%-72520500.000+21%-74306916.667+24%-71206850.000+19%-64645379.310+8%
Usd Revenue----5500.0000%32500.000-100%28500.000-100%1944600.000-100%1341103.448-100%
Usd Total Gains Per Share---0.168-0.087-48%-0.150-11%-0.179+6%-0.051-70%0.061-377%
 EOD+3 -5MRQTTM+7 -27YOY+10 -243Y+15 -195Y+8 -2610Y+8 -26

3.3 Fundamental Score

Let's check the fundamental score of Allogene Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.099
Price to Book Ratio (EOD)Between0-10.681
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than117.242
Current Ratio (MRQ)Greater than19.712
Debt to Asset Ratio (MRQ)Less than10.241
Debt to Equity Ratio (MRQ)Less than10.318
Return on Equity (MRQ)Greater than0.15-0.155
Return on Assets (MRQ)Greater than0.05-0.118
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Allogene Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.544
Ma 20Greater thanMa 501.293
Ma 50Greater thanMa 1001.299
Ma 100Greater thanMa 2001.517
OpenGreater thanClose1.190
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Allogene Therapeutics Inc

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-06-18 22:54:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Allogene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allogene Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM68,112.5%-68,112.5%
TTM68,112.5%YOY-255,940.5%+324,053.0%
TTM68,112.5%5Y-99,679.9%+167,792.4%
5Y-99,679.9%10Y-68,744.8%-30,935.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM68,112.5%-141.4%+68,253.9%
YOY-255,940.5%-186.1%-255,754.4%
3Y-116,271.8%-248.3%-116,023.5%
5Y-99,679.9%-338.6%-99,341.3%
10Y-68,744.8%-488.9%-68,255.9%
4.3.1.2. Return on Assets

Shows how efficient Allogene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • -11.8% Return on Assets means that Allogene generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allogene Therapeutics Inc:

  • The MRQ is -11.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-11.0%-0.7%
TTM-11.0%YOY-10.8%-0.3%
TTM-11.0%5Y-8.8%-2.2%
5Y-8.8%10Y-9.4%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.8%-11.5%-0.3%
TTM-11.0%-11.6%+0.6%
YOY-10.8%-11.4%+0.6%
3Y-10.8%-11.8%+1.0%
5Y-8.8%-12.1%+3.3%
10Y-9.4%-13.8%+4.4%
4.3.1.3. Return on Equity

Shows how efficient Allogene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • -15.5% Return on Equity means Allogene generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allogene Therapeutics Inc:

  • The MRQ is -15.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.5%TTM-14.2%-1.3%
TTM-14.2%YOY-13.5%-0.8%
TTM-14.2%5Y-10.7%-3.5%
5Y-10.7%10Y-10.5%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.5%-13.6%-1.9%
TTM-14.2%-14.9%+0.7%
YOY-13.5%-14.4%+0.9%
3Y-13.5%-17.0%+3.5%
5Y-10.7%-17.9%+7.2%
10Y-10.5%-20.1%+9.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Allogene Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Allogene is operating .

  • Measures how much profit Allogene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allogene Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM67,517.0%-67,517.0%
TTM67,517.0%YOY-247,071.5%+314,588.6%
TTM67,517.0%5Y-97,226.6%+164,743.7%
5Y-97,226.6%10Y-67,052.8%-30,173.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM67,517.0%-250.3%+67,767.3%
YOY-247,071.5%-205.1%-246,866.4%
3Y-112,197.5%-220.2%-111,977.3%
5Y-97,226.6%-342.6%-96,884.0%
10Y-67,052.8%-475.5%-66,577.3%
4.3.2.2. Operating Ratio

Measures how efficient Allogene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-687.386+687.386
TTM-687.386YOY3,203.407-3,890.793
TTM-687.3865Y1,319.079-2,006.465
5Y1,319.07910Y909.710+409.369
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-687.3862.704-690.090
YOY3,203.4073.063+3,200.344
3Y1,507.9043.576+1,504.328
5Y1,319.0794.713+1,314.366
10Y909.7106.512+903.198
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Allogene Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Allogene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.71 means the company has $9.71 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 9.712. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.963. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.712TTM9.963-0.251
TTM9.963YOY11.734-1.771
TTM9.9635Y12.075-2.112
5Y12.07510Y12.765-0.690
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.7123.661+6.051
TTM9.9633.786+6.177
YOY11.7344.121+7.613
3Y10.6824.680+6.002
5Y12.0755.765+6.310
10Y12.7656.150+6.615
4.4.3.2. Quick Ratio

Measures if Allogene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Quick Ratio of 17.24 means the company can pay off $17.24 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 17.242. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 16.809. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.242TTM16.809+0.432
TTM16.809YOY20.859-4.050
TTM16.8095Y20.850-4.041
5Y20.85010Y21.397-0.547
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2422.826+14.416
TTM16.8093.128+13.681
YOY20.8593.782+17.077
3Y18.7964.304+14.492
5Y20.8505.703+15.147
10Y21.3976.454+14.943
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Allogene Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Allogene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Allogene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Allogene assets are financed with 24.1% credit (debt) and the remaining percentage (100% - 24.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 0.241. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.222. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.241TTM0.222+0.019
TTM0.222YOY0.197+0.025
TTM0.2225Y0.159+0.063
5Y0.15910Y0.186-0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2410.324-0.083
TTM0.2220.347-0.125
YOY0.1970.327-0.130
3Y0.1990.339-0.140
5Y0.1590.349-0.190
10Y0.1860.382-0.196
4.5.4.2. Debt to Equity Ratio

Measures if Allogene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Allogene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.8% means that company has $0.32 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allogene Therapeutics Inc:

  • The MRQ is 0.318. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.286. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.318TTM0.286+0.032
TTM0.286YOY0.246+0.040
TTM0.2865Y0.194+0.092
5Y0.19410Y0.161+0.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3180.383-0.065
TTM0.2860.436-0.150
YOY0.2460.410-0.164
3Y0.2500.446-0.196
5Y0.1940.460-0.266
10Y0.1610.509-0.348
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Allogene generates.

  • Above 15 is considered overpriced but always compare Allogene to the Biotechnology industry mean.
  • A PE ratio of -1.34 means the investor is paying $-1.34 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allogene Therapeutics Inc:

  • The EOD is -1.099. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.337. Based on the earnings, the company is expensive. -2
  • The TTM is -1.877. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.099MRQ-1.337+0.238
MRQ-1.337TTM-1.877+0.541
TTM-1.877YOY-3.030+1.152
TTM-1.8775Y-12.240+10.362
5Y-12.24010Y-15.547+3.308
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.099-2.197+1.098
MRQ-1.337-2.027+0.690
TTM-1.877-2.527+0.650
YOY-3.030-3.733+0.703
3Y-3.452-3.717+0.265
5Y-12.240-6.036-6.204
10Y-15.547-6.649-8.898
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allogene Therapeutics Inc:

  • The EOD is -1.237. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.506. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.525. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.237MRQ-1.506+0.268
MRQ-1.506TTM-2.525+1.019
TTM-2.525YOY-3.781+1.256
TTM-2.5255Y-15.781+13.256
5Y-15.78110Y-18.469+2.688
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.237-3.007+1.770
MRQ-1.506-2.704+1.198
TTM-2.525-3.627+1.102
YOY-3.781-4.334+0.553
3Y-5.095-5.070-0.025
5Y-15.781-8.532-7.249
10Y-18.469-9.305-9.164
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Allogene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.83 means the investor is paying $0.83 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Allogene Therapeutics Inc:

  • The EOD is 0.681. Based on the equity, the company is cheap. +2
  • The MRQ is 0.829. Based on the equity, the company is cheap. +2
  • The TTM is 1.061. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.681MRQ0.829-0.148
MRQ0.829TTM1.061-0.232
TTM1.061YOY1.606-0.545
TTM1.0615Y3.294-2.233
5Y3.29410Y4.074-0.781
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6811.921-1.240
MRQ0.8291.843-1.014
TTM1.0612.113-1.052
YOY1.6062.467-0.861
3Y1.7382.541-0.803
5Y3.2943.666-0.372
10Y4.0744.311-0.237
4.6.2. Total Gains per Share

2.4. Latest News of Allogene Therapeutics Inc

Does Allogene Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Allogene Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-14
17:46
Allogene's SWOT analysis: stock outlook amid clinical delays, promising dataRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Allogene Therapeutics Inc.

4.8.1. Institutions holding Allogene Therapeutics Inc

Institutions are holding 80.59% of the shares of Allogene Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Pfizer Inc10.07276.42262203204000
2025-03-31TPG GP A, LLC8.55680.53891871630600
2025-03-31BlackRock Inc8.19860.000617932906-129749-0.7183
2025-03-31Capital World Investors5.60750.002912265330536877877.8473
2025-03-31Darwin Global Management, Ltd.4.77751.107110449791104497910
2025-03-31Citadel Advisors Llc4.66480.002810203329485423390.7487
2025-03-31Vanguard Group Inc3.68830.00028067553668610.8357
2025-03-31FMR Inc3.38050.00077394162-16377833-68.8955
2025-03-31Goldman Sachs Group Inc2.67630.001458539743747397177.8903
2025-03-31JPMorgan Chase & Co2.34850.00065136797140066537.4897
2025-03-31PRIMECAP Management Company2.25480.006493184045000.0913
2025-03-31Woodline Partners LP1.99360.041443606083760.0086
2025-03-31T. Rowe Price Associates, Inc.1.92290.00084206004-279568-6.2326
2025-03-31Foresite Capital Management VI LLC1.57652.7579344827500
2025-03-31Geode Capital Management, LLC1.53590.000433594381268203.9231
2025-03-31Dimensional Fund Advisors, Inc.1.45380.00123179853-381773-10.7191
2025-03-31Wildcat Capital Management, LLC1.33532.2757292078700
2025-03-31State Street Corp1.27540.00022789777-4460189-61.5201
2025-03-31Patient Square Capital1.08271.4304236818687827758.9484
2025-03-31Morgan Stanley - Brokerage Accounts1.07580.000323531011354505135.6409
Total 69.478214.5921151970057+6623091+4.4%

4.9.2. Funds holding Allogene Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31American Funds SMALLCAP World A5.60750.026112265330536877877.8473
2025-04-30Vanguard Total Stock Mkt Idx Inv1.95590.0004427805600
2025-05-31iShares Russell 2000 ETF1.46010.0061319358900
2025-03-31Vanguard Capital Opportunity Inv1.35540.02032964570-4800-0.1617
2025-03-31T. Rowe Price Health Sciences1.34230.03482936094-44337-1.4876
2025-02-28BGF World Healthscience A2 USD1.12840.0341246824600
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.0790.003923601048070.0342
2025-03-31PRIMECAP Odyssey Aggressive Growth0.84030.04531837970100000.5471
2025-03-31Fidelity Small Cap Growth0.71640.034156696700
2025-04-30JPMorgan Small Cap Growth A0.66830.0813146187500
2025-04-30BlackRock Health Sciences Opps Inv A0.64620.0344141352700
2025-03-31Fidelity Small Cap Index0.58740.0078128482162530.4891
2025-05-31iShares Russell 2000 Value ETF0.52380.0125114565100
2025-04-30Fidelity Select Biotechnology0.4340.040994921500
2025-04-30JPM Thematics Genetic Thrps C2 dist USD0.39810.3769870760-25056-2.797
2025-05-31abrdn Life Sciences Investors0.39650.253586725000
2025-04-30Fidelity Extended Market Index0.38420.0039840462-8033-0.9467
2025-05-31iShares Biotechnology ETF0.35970.018478678300
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.33790.002173919600
2025-03-31BlackRock Health Sciences Term Trust0.33350.073772956000
Total 20.55491.110444960026+5303612+11.8%

5.3. Insider Transactions

Insiders are holding 17.742% of the shares of Allogene Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-21Annie YoshiyamaSELL96011.41
2025-03-14Benjamin Machinas BeneskiSELL54881.98
2025-03-14David D ChangSELL466681.96
2025-02-03Earl Martin DouglasSELL64041.71
2025-02-03Geoffrey M ParkerSELL43611.73
2025-02-03Timothy L MooreSELL147461.71
2025-01-21Zachary RobertsSELL271991.78
2024-12-09Deborah M MessemerSELL91362.18
2024-12-05Franz B HumerSELL92212.16
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets507,982
Total Liabilities122,589
Total Stockholder Equity385,393
 As reported
Total Liabilities 122,589
Total Stockholder Equity+ 385,393
Total Assets = 507,982

Assets

Total Assets507,982
Total Current Assets291,576
Long-term Assets216,406
Total Current Assets
Cash And Cash Equivalents 42,455
Short-term Investments 237,588
Other Current Assets 11,533
Total Current Assets  (as reported)291,576
Total Current Assets  (calculated)291,576
+/-0
Long-term Assets
Property Plant Equipment 127,067
Long Term Investments 55,506
Long-term Assets Other 33,833
Long-term Assets  (as reported)216,406
Long-term Assets  (calculated)216,406
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities30,022
Long-term Liabilities92,567
Total Stockholder Equity385,393
Total Current Liabilities
Accounts payable 5,058
Other Current Liabilities 49,928
Total Current Liabilities  (as reported)30,022
Total Current Liabilities  (calculated)54,986
+/- 24,964
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt81,292
Long-term Liabilities Other 11,275
Long-term Liabilities  (as reported)92,567
Long-term Liabilities  (calculated)92,567
+/-0
Total Stockholder Equity
Common Stock219
Retained Earnings -1,879,556
Accumulated Other Comprehensive Income 43
Other Stockholders Equity 2,264,687
Total Stockholder Equity (as reported)385,393
Total Stockholder Equity (calculated)385,393
+/-0
Other
Capital Stock219
Cash and Short Term Investments 280,043
Common Stock Shares Outstanding 215,359
Liabilities and Stockholders Equity 507,982
Net Debt 38,837
Net Invested Capital 385,393
Net Working Capital 261,554
Property Plant and Equipment Gross 192,704
Short Long Term Debt Total 81,292



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
0
148,845
298,845
435,235
773,855
749,369
733,997
695,544
717,802
688,523
1,258,544
1,222,500
1,227,829
1,179,044
1,126,724
1,079,246
1,038,634
964,632
947,644
887,572
817,079
746,871
770,971
712,326
642,837
586,350
646,883
589,120
548,710
507,982
507,982548,710589,120646,883586,350642,837712,326770,971746,871817,079887,572947,644964,6321,038,6341,079,2461,126,7241,179,0441,227,8291,222,5001,258,544688,523717,802695,544733,997749,369773,855435,235298,845148,8450
   > Total Current Assets 
0
144,264
294,264
247,353
467,982
476,627
511,542
509,757
544,576
504,414
909,577
854,058
845,130
716,061
602,171
502,858
809,481
469,744
513,028
569,061
528,824
514,012
502,101
473,454
459,115
395,364
457,124
304,415
303,386
291,576
291,576303,386304,415457,124395,364459,115473,454502,101514,012528,824569,061513,028469,744809,481502,858602,171716,061845,130854,058909,577504,414544,576509,757511,542476,627467,982247,353294,264144,2640
       Cash And Cash Equivalents 
0
143,927
293,927
83,141
721,350
92,748
650,193
160,990
588,855
135,897
280,379
1,049,015
1,032,118
236,865
223,503
190,021
809,481
84,514
96,041
74,357
576,471
514,012
154,758
69,246
83,155
51,039
170,667
51,239
75,218
42,455
42,45575,21851,239170,66751,03983,15569,246154,758514,012576,47174,35796,04184,514809,481190,021223,503236,8651,032,1181,049,015280,379135,897588,855160,990650,19392,748721,35083,141293,927143,9270
       Short-term Investments 
0
0
0
161,080
366,952
373,392
389,840
340,254
355,407
357,026
619,271
682,886
644,559
462,716
364,204
293,464
283,988
364,536
394,451
477,872
455,416
361,293
337,204
396,259
365,542
333,821
273,961
240,325
217,258
237,588
237,588217,258240,325273,961333,821365,542396,259337,204361,293455,416477,872394,451364,536283,988293,464364,204462,716644,559682,886619,271357,026355,407340,254389,840373,392366,952161,080000
       Net Receivables 
0
0
0
0
3,108
3,391
3,285
2,337
2,403
200
800
2,274
5,169
6,275
4,300
6,160
5,815
9,042
11,900
5,800
3,300
2,200
1,100
1,600
1,700
1,700
2,000
0
0
0
0002,0001,7001,7001,6001,1002,2003,3005,80011,9009,0425,8156,1604,3006,2755,1692,2748002002,4032,3373,2853,3913,1080000
       Other Current Assets 
0
0
337
6,264
5,490
7,096
5,833
6,176
11,640
11,291
9,127
9,936
10,620
11,980
10,164
9,973
8,021
9,394
10,636
11,032
11,504
10,241
10,139
7,949
10,418
10,504
12,496
12,851
9,010
11,533
11,5339,01012,85112,49610,50410,4187,94910,13910,24111,50411,03210,6369,3948,0219,97310,16411,98010,6209,9369,12711,29111,6406,1765,8337,0965,4906,26433700
   > Long-term Assets 
0
0
4,581
187,882
305,873
272,742
222,455
185,787
173,226
184,109
348,967
368,442
382,699
462,983
524,553
576,388
229,153
494,888
434,616
318,511
288,255
232,859
268,870
238,872
183,722
190,986
189,759
284,705
245,324
216,406
216,406245,324284,705189,759190,986183,722238,872268,870232,859288,255318,511434,616494,888229,153576,388524,553462,983382,699368,442348,967184,109173,226185,787222,455272,742305,873187,8824,58100
       Property Plant Equipment 
0
3,526
3,526
29,689
41,610
52,820
67,697
77,380
100,944
110,185
127,037
144,210
160,135
163,335
164,933
164,647
181,020
177,257
204,053
199,687
196,431
191,813
186,700
181,469
163,181
160,414
150,465
135,302
131,261
127,067
127,067131,261135,302150,465160,414163,181181,469186,700191,813196,431199,687204,053177,257181,020164,647164,933163,335160,135144,210127,037110,185100,94477,38067,69752,82041,61029,6893,5263,5260
       Long Term Investments 
0
0
0
154,045
261,966
214,588
147,769
100,702
63,214
64,950
215,471
212,509
204,208
283,924
344,342
396,132
352,179
298,297
211,333
99,154
71,968
53,912
62,496
37,535
3,645
15,121
1,134
111,821
80,673
55,506
55,50680,673111,8211,13415,1213,64537,53562,49653,91271,96899,154211,333298,297352,179396,132344,342283,924204,208212,509215,47164,95063,214100,702147,769214,588261,966154,045000
       Intangible Assets 
0
1,055
1,055
904
754
603
452
301
151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001513014526037549041,0551,0550
       Other Assets 
0
0
1,055
3,244
1,543
4,731
6,537
7,404
8,917
8,974
6,459
265,789
263,859
15,724
15,278
15,609
16,107
16,334
16,230
16,670
16,856
0
16,674
0
0
0
0
0
0
0
000000016,674016,85616,67016,23016,33416,10715,60915,27815,724263,859265,7896,4598,9748,9177,4046,5374,7311,5433,2441,05500
> Total Liabilities 
2
17,233
17,233
603,678
70,691
68,141
78,362
75,828
88,779
82,004
95,125
103,769
148,212
109,265
102,912
109,304
122,228
109,402
145,695
147,611
151,209
154,609
148,065
129,224
130,604
124,983
131,845
125,372
126,531
122,589
122,589126,531125,372131,845124,983130,604129,224148,065154,609151,209147,611145,695109,402122,228109,304102,912109,265148,212103,76995,12582,00488,77975,82878,36268,14170,691603,67817,23317,2332
   > Total Current Liabilities 
2
14,745
14,745
159,477
29,459
27,265
38,000
33,354
33,079
26,818
40,895
50,130
94,320
54,849
45,998
53,490
48,174
36,877
44,909
48,872
54,518
59,585
54,721
37,636
37,079
30,894
37,305
32,571
35,523
30,022
30,02235,52332,57137,30530,89437,07937,63654,72159,58554,51848,87244,90936,87748,17453,49045,99854,84994,32050,13040,89526,81833,07933,35438,00027,26529,459159,47714,74514,7452
       Short-term Debt 
0
0
0
139,615
0
0
0
0
1,679
0
0
50,846
2,974
51,625
0
0
3,200
0
5,344
5,831
6,002
6,189
6,381
6,578
6,775
6,930
7,221
0
7,509
0
07,50907,2216,9306,7756,5786,3816,1896,0025,8315,34403,2000051,6252,97450,846001,6790000139,615000
       Accounts payable 
0
1,268
1,268
3,083
12,338
12,976
23,503
8,047
9,250
7,199
9,057
10,151
10,390
14,875
11,005
11,499
10,255
8,708
9,713
11,045
13,890
14,688
10,229
6,205
5,897
5,779
12,936
5,506
5,394
5,058
5,0585,3945,50612,9365,7795,8976,20510,22914,68813,89011,0459,7138,70810,25511,49911,00514,87510,39010,1519,0577,1999,2508,04723,50312,97612,3383,0831,2681,2680
       Other Current Liabilities 
2
3,079
13,477
16,779
17,121
14,289
14,497
25,307
22,150
19,619
31,838
39,979
41,964
39,735
34,688
41,626
34,296
27,763
29,016
31,107
33,741
38,435
44,263
24,617
24,321
18,099
24,369
27,065
22,620
49,928
49,92822,62027,06524,36918,09924,32124,61744,26338,43533,74131,10729,01627,76334,29641,62634,68839,73541,96439,97931,83819,61922,15025,30714,49714,28917,12116,77913,4773,0792
   > Long-term Liabilities 
0
0
2,488
444,201
41,232
40,876
40,362
42,474
55,700
55,186
54,230
53,639
53,892
54,416
56,914
55,814
74,054
72,525
100,786
98,739
96,691
95,024
93,344
91,588
93,525
94,089
94,540
92,801
91,008
92,567
92,56791,00892,80194,54094,08993,52591,58893,34495,02496,69198,739100,78672,52574,05455,81456,91454,41653,89253,63954,23055,18655,70042,47440,36240,87641,232444,2012,48800
       Warrants
0
0
0
411,052
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000411,052000
       Other Liabilities 
0
2,488
2,488
7,488
6,776
6,065
5,495
4,785
4,351
3,650
3,163
2,793
3,083
2,791
5,705
5,175
4,125
3,490
2,554
2,033
1,569
0
0
0
0
0
0
0
0
0
0000000001,5692,0332,5543,4904,1255,1755,7052,7913,0832,7933,1633,6504,3514,7855,4956,0656,7767,4882,4882,4880
       Deferred Long Term Liability 
0
0
0
2,200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000002,200000
> Total Stockholder Equity
-2
-2
281,612
-168,443
703,164
681,228
655,635
619,716
629,023
606,519
1,163,419
1,118,731
1,079,617
1,069,779
1,023,812
969,942
916,406
855,230
801,949
739,961
665,870
592,262
622,906
583,102
512,233
461,367
515,038
463,748
422,179
385,393
385,393422,179463,748515,038461,367512,233583,102622,906592,262665,870739,961801,949855,230916,406969,9421,023,8121,069,7791,079,6171,118,7311,163,419606,519629,023619,716655,635681,228703,164-168,443281,612-2-2
   Retained Earnings -1,879,556-1,819,823-1,759,884-1,693,591-1,627,233-1,562,233-1,473,988-1,412,673-1,334,684-1,235,980-1,141,133-1,057,985-983,198-903,348-828,480-750,294-679,358-646,343-577,773-511,576-450,602-396,122-335,092-284,357-243,114-211,528-181,019-137,522-137,501-2
   Accumulated Other Comprehensive Income 
0
-2
-261,052
-148
306
1,405
2,161
1,866
1,145
1,610
1,830
953
268
-101
-334
-398
-2,567
-9,249
-11,472
-12,958
-9,926
-5,934
-3,851
-2,411
-955
-927
-780
157
-89
43
43-89157-780-927-955-2,411-3,851-5,934-9,926-12,958-11,472-9,249-2,567-398-334-1012689531,8301,6101,1451,8662,1611,405306-148-261,052-20
   Capital Surplus 
0
0
0
12,693
914,265
922,816
937,709
952,820
1,023,876
1,055,386
1,673,026
1,695,411
1,725,552
1,749,097
1,774,298
1,798,678
1,822,179
1,847,534
1,871,262
1,893,908
0
1,932,734
2,039,263
0
0
0
0
0
0
0
00000002,039,2631,932,73401,893,9081,871,2621,847,5341,822,1791,798,6781,774,2981,749,0971,725,5521,695,4111,673,0261,055,3861,023,876952,820937,709922,816914,26512,693000
   Treasury Stock000000000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue22
Cost of Revenue-13,639
Gross Profit-192,277-13,617
 
Operating Income (+$)
Gross Profit-192,277
Operating Expense-273,221
Operating Income-273,199-465,498
 
Operating Expense (+$)
Research Development192,299
Selling General Administrative65,205
Selling And Marketing Expenses0
Operating Expense273,221257,504
 
Net Interest Income (+$)
Interest Income20,153
Interest Expense-181
Other Finance Cost-0
Net Interest Income19,972
 
Pretax Income (+$)
Operating Income-273,199
Net Interest Income19,972
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-257,147-289,251
EBIT - interestExpense = -257,147
-257,147
-257,409
Interest Expense181
Earnings Before Interest and Taxes (EBIT)-256,966-256,966
Earnings Before Interest and Taxes (EBITDA)-243,327
 
After tax Income (+$)
Income Before Tax-257,147
Tax Provision-443
Net Income From Continuing Ops-257,590-257,590
Net Income-257,590
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses273,221
Total Other Income/Expenses Net16,052-19,972
 

Technical Analysis of Allogene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allogene. The general trend of Allogene is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allogene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Allogene Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allogene Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.51 < 1.75 < 1.78.

The bearish price targets are: 1.02 > 0.8621.

Know someone who trades $ALLO? Share this with them.👇

Allogene Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allogene Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allogene Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allogene Therapeutics Inc. The current macd is -0.03205751.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Allogene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Allogene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Allogene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Allogene Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAllogene Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allogene Therapeutics Inc. The current adx is 17.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Allogene shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Allogene Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allogene Therapeutics Inc. The current sar is 1.30368339.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Allogene Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allogene Therapeutics Inc. The current rsi is 44.54. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Allogene Therapeutics Inc Daily Relative Strength Index (RSI) ChartAllogene Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allogene Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Allogene price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Allogene Therapeutics Inc Daily Stochastic Oscillator ChartAllogene Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allogene Therapeutics Inc. The current cci is -63.87318938.

Allogene Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAllogene Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allogene Therapeutics Inc. The current cmo is -12.99109935.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Allogene Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAllogene Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allogene Therapeutics Inc. The current willr is -73.52941176.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Allogene is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Allogene Therapeutics Inc Daily Williams %R ChartAllogene Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Allogene Therapeutics Inc.

Allogene Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allogene Therapeutics Inc. The current atr is 0.10035665.

Allogene Therapeutics Inc Daily Average True Range (ATR) ChartAllogene Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allogene Therapeutics Inc. The current obv is 28,940,686.

Allogene Therapeutics Inc Daily On-Balance Volume (OBV) ChartAllogene Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allogene Therapeutics Inc. The current mfi is 31.22.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Allogene Therapeutics Inc Daily Money Flow Index (MFI) ChartAllogene Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allogene Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Allogene Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allogene Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.544
Ma 20Greater thanMa 501.293
Ma 50Greater thanMa 1001.299
Ma 100Greater thanMa 2001.517
OpenGreater thanClose1.190
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Allogene with someone you think should read this too:
  • Are you bullish or bearish on Allogene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allogene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allogene Therapeutics Inc

I send you an email if I find something interesting about Allogene Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Allogene Therapeutics Inc.

Receive notifications about Allogene Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.